Clinical Trials
23 trialsNCT03456076 2026-05-05
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05104866 2026-05-05
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT02486718 2026-04-30
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04083235 2026-04-20
NAPOLI 3
Ipsen
Phase 3 Completed
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT04003636 2026-03-24
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT03088540 2026-02-23
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04223856 2025-06-13
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT04974398 2025-04-13
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
Phase 3 Active not recruiting
NCT03425643 2024-12-03
MK-3475-671
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT02409342 2023-03-15
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Hoffmann-La Roche
Phase 3 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed